NPI: 1568461440 · BECKLEY, WV 25801 · General Acute Care Hospital · NPI assigned 07/21/2005
Authorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
| Authorized Official | HARRIS, HOLLIE (PRESIDENT AND CEO) |
| NPI Enumeration Date | 07/21/2005 |
Other providers sharing the same authorized official: HARRIS, HOLLIE
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 139,235 | $5.96M |
| 2019 | 86,049 | $2.74M |
| 2020 | 111,391 | $4.08M |
| 2021 | 83,259 | $1.82M |
| 2022 | 48,571 | $1.26M |
| 2023 | 45,906 | $1.34M |
| 2024 | 39,636 | $1.14M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 15,777 | 13,315 | $1.77M |
| 41899 | Unlisted procedure, dentoalveolar structures | 1,566 | 1,318 | $1.61M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5,289 | 4,388 | $1.29M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 15,321 | 13,553 | $1.14M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 52,706 | 39,093 | $628K |
| 80053 | Comprehensive metabolic panel | 41,905 | 33,084 | $595K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 11,572 | 9,697 | $525K |
| G0378 | Hospital observation service, per hour | 1,042 | 651 | $448K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 7,110 | 5,755 | $444K |
| 36415 | Collection of venous blood by venipuncture | 34,794 | 24,549 | $444K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1,220 | 1,099 | $417K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3,181 | 2,733 | $355K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 7,855 | 6,577 | $333K |
| 70450 | Computed tomography, head or brain; without contrast material | 4,103 | 3,495 | $278K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6,605 | 1,697 | $263K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3,506 | 2,632 | $222K |
| 84443 | Thyroid stimulating hormone (TSH) | 12,240 | 10,884 | $217K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 15,153 | 11,476 | $207K |
| 81001 | 17,500 | 14,518 | $202K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 5,523 | 4,022 | $199K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1,008 | 812 | $195K |
| 84484 | 10,658 | 7,729 | $169K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 417 | 332 | $168K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 7,053 | 5,811 | $165K |
| 80061 | Lipid panel | 9,251 | 8,475 | $146K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,014 | 2,334 | $144K |
| 71045 | Radiologic examination, chest; single view | 9,917 | 8,191 | $144K |
| 83735 | 12,027 | 8,072 | $136K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4,834 | 4,045 | $132K |
| 87040 | 5,502 | 3,852 | $127K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 17,896 | 15,276 | $124K |
| 82150 | 3,688 | 2,994 | $124K | |
| 83690 | 6,462 | 5,358 | $113K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1,222 | 861 | $109K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 3,897 | 2,962 | $108K |
| 85730 | 5,588 | 4,538 | $108K | |
| 82553 | 5,940 | 4,459 | $108K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2,308 | 1,934 | $103K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1,608 | 1,473 | $100K |
| 85610 | 7,687 | 6,159 | $99K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 4,747 | 3,714 | $98K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 985 | 697 | $95K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2,311 | 749 | $94K |
| 83605 | 4,614 | 3,656 | $94K | |
| 82550 | 6,397 | 4,845 | $91K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 6,096 | 4,219 | $88K |
| 84703 | 2,058 | 1,669 | $88K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 172 | 158 | $83K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 876 | 678 | $80K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 547 | 491 | $77K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1,701 | 1,190 | $76K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 539 | 421 | $74K |
| 74178 | 282 | 233 | $70K | |
| 83880 | 3,195 | 2,586 | $69K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 4,212 | 3,613 | $68K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 409 | 326 | $68K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 5,612 | 4,988 | $68K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1,050 | 943 | $68K |
| 83036 | Hemoglobin; glycosylated (A1C) | 6,887 | 6,322 | $66K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2,241 | 1,927 | $65K |
| 88312 | 1,007 | 891 | $63K | |
| 73560 | 3,129 | 2,879 | $63K | |
| J2785 | Injection, regadenoson, 0.1 mg | 357 | 269 | $63K |
| 96367 | 1,389 | 842 | $62K | |
| 71046 | Radiologic examination, chest; 2 views | 3,524 | 3,078 | $60K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1,130 | 422 | $59K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 630 | 420 | $58K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 3,129 | 1,348 | $58K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 864 | 704 | $56K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 10,728 | 9,042 | $55K |
| 96376 | 1,279 | 762 | $52K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 645 | 565 | $51K |
| 73030 | 1,550 | 1,394 | $50K | |
| 84145 | 2,442 | 1,892 | $48K | |
| 80076 | 3,471 | 3,157 | $47K | |
| 86140 | 3,005 | 2,432 | $45K | |
| 80299 | 285 | 229 | $45K | |
| 93017 | 556 | 439 | $44K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2,453 | 2,343 | $44K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 501 | 451 | $43K |
| 81025 | 4,297 | 3,608 | $41K | |
| 72131 | 372 | 318 | $41K | |
| 85652 | 3,142 | 2,580 | $41K | |
| 82607 | 3,235 | 2,996 | $38K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 572 | 166 | $34K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 2,960 | 1,762 | $34K |
| 87522 | Neg quan hep c or qual rna | 844 | 728 | $34K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1,318 | 1,136 | $33K |
| 87186 | 1,832 | 1,574 | $31K | |
| 84439 | 2,519 | 2,252 | $29K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 243 | 217 | $29K |
| 93971 | 467 | 407 | $29K | |
| 80074 | 851 | 763 | $28K | |
| 87070 | 860 | 697 | $27K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1,007 | 852 | $27K |
| 93041 | 3,129 | 2,294 | $26K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 847 | 787 | $26K |
| 72100 | 945 | 863 | $26K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 385 | 337 | $24K |
| A9270 | Non-covered item or service | 2,468 | 1,031 | $24K |
| 78454 | 104 | 77 | $23K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 1,746 | 1,251 | $23K |
| J0690 | Injection, cefazolin sodium, 500 mg | 308 | 234 | $22K |
| 82803 | 750 | 552 | $20K | |
| J3490 | Unclassified drugs | 1,028 | 516 | $19K |
| 73610 | 590 | 499 | $18K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 901 | 862 | $18K |
| 80069 | 1,276 | 726 | $18K | |
| 84100 | 1,257 | 734 | $18K | |
| 73630 | 574 | 499 | $18K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 368 | 261 | $17K |
| 93458 | 75 | 51 | $17K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 746 | 458 | $17K |
| 73130 | 444 | 359 | $17K | |
| 87077 | 851 | 724 | $17K | |
| 36591 | 138 | 50 | $16K | |
| 73110 | 467 | 347 | $16K | |
| 74018 | 793 | 689 | $16K | |
| 71250 | 269 | 238 | $15K | |
| 88304 | 312 | 268 | $15K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 20 | 13 | $13K |
| 80164 | 990 | 923 | $13K | |
| 82565 | 1,212 | 1,131 | $13K | |
| 82728 | 1,047 | 945 | $13K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 475 | 361 | $12K |
| 73562 | 658 | 571 | $12K | |
| 97014 | 317 | 84 | $12K | |
| 36600 | 668 | 503 | $12K | |
| 97035 | 322 | 121 | $12K | |
| 81002 | 655 | 548 | $12K | |
| 84520 | 1,138 | 1,064 | $11K | |
| 83540 | 1,250 | 1,108 | $11K | |
| J1644 | Injection, heparin sodium, per 1000 units | 1,243 | 668 | $11K |
| 85378 | 885 | 737 | $11K | |
| 86592 | 519 | 463 | $11K | |
| 87076 | 1,087 | 940 | $11K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 396 | 291 | $10K |
| 99218 | 382 | 355 | $10K | |
| 82746 | 894 | 813 | $10K | |
| 80050 | General health panel | 412 | 401 | $10K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 183 | 58 | $9K |
| 84702 | 296 | 265 | $9K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 232 | 212 | $9K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 183 | 132 | $8K |
| 0100U | 179 | 141 | $8K | |
| 96368 | 82 | 55 | $8K | |
| J1956 | Injection, levofloxacin, 250 mg | 110 | 66 | $8K |
| 82140 | 665 | 521 | $7K | |
| 84436 | 304 | 270 | $7K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 252 | 101 | $7K |
| 83883 | 117 | 95 | $7K | |
| 86706 | 215 | 168 | $7K | |
| 86708 | 184 | 143 | $6K | |
| 97162 | 174 | 156 | $6K | |
| 73502 | 287 | 268 | $6K | |
| 83550 | 748 | 680 | $6K | |
| 86704 | 181 | 138 | $6K | |
| 87340 | 184 | 143 | $6K | |
| 87631 | 113 | 107 | $6K | |
| 85379 | 299 | 227 | $6K | |
| 83010 | 158 | 126 | $5K | |
| 72040 | 155 | 140 | $4K | |
| 94060 | 287 | 271 | $4K | |
| C1769 | Guide wire | 405 | 305 | $4K |
| 87902 | 40 | 28 | $4K | |
| 80202 | 340 | 147 | $4K | |
| 73522 | 86 | 76 | $3K | |
| 86901 | 125 | 81 | $3K | |
| 86900 | 125 | 81 | $3K | |
| 94729 | 174 | 165 | $3K | |
| 94726 | 189 | 176 | $3K | |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1,630 | 1,543 | $3K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 64 | 28 | $3K |
| 82977 | 71 | 59 | $3K | |
| 76000 | 91 | 66 | $3K | |
| 84153 | 148 | 130 | $3K | |
| 82248 | 104 | 89 | $3K | |
| 74022 | 89 | 76 | $3K | |
| 86707 | 67 | 55 | $2K | |
| 87350 | 67 | 54 | $2K | |
| 84460 | 66 | 51 | $2K | |
| 84550 | 290 | 213 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 68 | 60 | $2K |
| 87536 | 68 | 53 | $2K | |
| 82652 | 68 | 64 | $2K | |
| 93970 | 27 | 26 | $2K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 15 | 15 | $2K |
| 82247 | 51 | 38 | $2K | |
| 82172 | 36 | 26 | $2K | |
| 80178 | 153 | 140 | $2K | |
| 86709 | 65 | 53 | $2K | |
| 82009 | 33 | 26 | $2K | |
| 87634 | 30 | 27 | $1K | |
| 92523 | 15 | 12 | $1K | |
| 80143 | 96 | 89 | $1K | |
| G0008 | Administration of influenza virus vaccine | 32 | 30 | $1K |
| 73080 | 42 | 35 | $1K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 30 | 24 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 97 | 88 | $1K |
| 82043 | 285 | 272 | $1K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 49 | 44 | $1K |
| 84480 | 66 | 57 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 26 | 26 | $1K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 13 | 13 | $961.27 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 98 | 87 | $927.12 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 15 | 15 | $881.19 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 15 | 15 | $881.19 |
| 83615 | 119 | 83 | $800.39 | |
| 76536 | 12 | 12 | $794.29 | |
| 97161 | 18 | 15 | $711.41 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 34 | 25 | $669.04 |
| 86850 | 80 | 53 | $668.80 | |
| 84146 | 29 | 28 | $655.28 | |
| 84479 | 55 | 46 | $622.01 | |
| 97166 | 12 | 12 | $591.78 | |
| 86360 | 19 | 14 | $575.09 | |
| 86359 | 19 | 14 | $575.01 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 66 | 27 | $503.93 |
| 94760 | 114 | 51 | $466.08 | |
| 73590 | 17 | 14 | $457.46 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 15 | 14 | $454.71 |
| 85027 | 94 | 76 | $433.77 | |
| 86703 | 47 | 43 | $413.55 | |
| 90662 | 12 | 12 | $391.75 | |
| 88142 | 13 | 13 | $374.36 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 15 | 14 | $344.85 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 50 | 42 | $323.79 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 22 | 13 | $281.67 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 26 | 26 | $274.24 |
| 81003 | 71 | 62 | $226.18 | |
| 82533 | 20 | 15 | $203.19 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 201 | 175 | $193.45 |
| 83921 | 13 | 12 | $191.85 | |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 77 | 76 | $181.25 |
| 83090 | 14 | 12 | $179.03 | |
| 80183 | 17 | 17 | $169.00 | |
| J2060 | Injection, lorazepam, 2 mg | 44 | 34 | $162.93 |
| 51702 | 13 | 12 | $143.30 | |
| 82570 | 40 | 40 | $124.99 | |
| 93246 | 16 | 16 | $123.98 | |
| 85045 | 16 | 12 | $123.28 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 14 | 13 | $106.88 |
| 81015 | 62 | 56 | $105.32 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 65 | 25 | $92.90 |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 48 | 48 | $87.87 |
| 99215 | Prolong outpt/office vis | 100 | 94 | $81.93 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 19 | 16 | $63.94 |
| 87449 | 22 | 14 | $58.50 | |
| 84156 | 14 | 14 | $44.39 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 51 | 42 | $34.99 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 17 | 12 | $21.84 |
| 80047 | 13 | 13 | $16.28 | |
| 90686 | 66 | 61 | $10.35 | |
| 83704 | 13 | 12 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 36 | 33 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 15 | 13 | $0.00 |